Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.incyte.com
Get the latest updates from Incyte Corporation News Releases directly as they happen.
Follow now 174 followers
Last updated 9 days ago
9 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 10, 2025-- Incyte (Nasdaq:INCY) announced today that it...
16 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jul. 2, 2025-- Incyte Corporation (Nasdaq: INCY) announced today...
23 days ago
- Three-decade industry leader, former CEO of Karuna and Anthos and Chief...
28 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 20, 2025-- Incyte (Nasdaq: INCY) today announced that...
about 1 month ago
- Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first...
about 1 month ago
QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for...
about 1 month ago
Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting...
about 1 month ago
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating...
about 1 month ago
WILMINGTON, Del. --(BUSINESS WIRE)--Jun. 6, 2025-- Incyte (Nasdaq:INCY) today announced that it...
about 2 months ago
Late-breaking oral presentation will highlight new data from a trial of INCA033989...
about 2 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--May 27, 2025-- Incyte (Nasdaq:INCY) announced today that it...
2 months ago
Zynyz ® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment...